A post about the ethical challenges of designer babies and the parallels this has two artificial intelligence.
Designer babies, which are genetically engineered (“gene-edited”) for desirable health, physical and intellectual features, are now within reach of current scientific know-how. They raise a host of societal and ethical questions, not unlike some of those brought about by recent advances in artificial intelligence (AI). There are also ways in which AI and gene-editing can become symbiotic, feeding on each other, both technologically and socially. Yet in some ways, both an ethically-clear path – by conceiving and treating gene editing is a public health measure for all – microphone of command and the guardrail institutions to support it may be within easier reach with designer babies than with AI.
The big breakthrough for gene editing came in the 2000s and especially the early 2010s, with the development of CRISPR-Cas9 technology, which enables high-precision genetic engineering. The technique uses a guide RNA to locate a specific sequence in the genome of a living organism, where the Cas9 enzyme makes a cut for disabling or editing a gene (for example, turning off a disease-inducing gene).
The applications are vast. The technique can be used to modify seeds and agricultural products and to design custom-made medicines and vaccines. It offers the potential to tackle inherited genetic diseases (such as sickle cell) as well as later-in-life, disease-inducing somatic mutations (such as those involved in cancer). It also raises the possibility that genes can be removed and new ones added in embryos, in vivo or in vitro, thus producing what is commonly referred to as “designer babies.” Human genetic engineering could be purely somatic (affecting the individual during their lifetime) or take the form of germline editing, altering the genome of an individual in a way that would be passed on to their offspring.
AI is technologically complementary to gene editing. AI can sift through massive amounts of data to find gene combinations that can change not just disease potential, but looks, physical strength and various dimensions of cognitive ability.
The promise is real – and so is the ethical conundrum. Designer babies can take us one step closer to a truly two-tier society. A group of wealthy humans would use this technology to improve their cognitive and physical performance, not just their lifespan, and with germline editing, would pass this on to their offspring, making one class of society not just richer but also superior in terms of various important characteristics. To the extent that cognitive ability can be engineered this way, even if imperfectly, their offspring will now have an even more formidable advantage, going beyond the already (arguably) unfair privilege of inheriting much greater levels of wealth much higher quality education. With their physique also engineered this way, they will plausibly become more and more likely to match within their class, laying the foundations of a society divided between the privileged, endowed with an array of desirable and superior characteristics, ruling over the rest.
This is not merely hypothetical. Embryo selection services based on polygenic screening are already sold commercially to IVF patients. AI makes this future both more likely and scarier, because it will likely create a cadre of billionaires and trillionaires intent on cementing their economic privileges with biological ones, while many people will struggle to find good jobs, or any jobs at all, especially if AI continues in an automation direction.
A first reaction to this prospect would be to ban germline editing and anything looking like designer babies altogether. But this may not be the right reaction.
We already “design” our bodies and our children by means of vaccines and operations. Parents in the industrialized world (and increasingly in the emerging world) test for a variety of diseases, such as Down syndrome, and can decide to undertake selective abortions. The line between these interventions and genome editing is not hard and fast, but amorphous. Why is it different to edit genes so that smallpox cannot occur than to inject children with a vaccine against smallpox?
The difference isn’t about interfering with nature or impacting the genome. It is about two other aspects of central importance.
First, the implications of germline editing are poorly understood. Living organisms are constantly attacked by pathogens, and some genetic changes, especially those passed from parents to offspring, can create unforeseen vulnerabilities. For example, the first gene-edited babies were born in China in 2018, as a result of the scientist He Jiankui editing the CCR5 gene to confer HIV resistance. But the same edit appears to increase susceptibility to other infections such as West Nile virus and influenza. We know what smallpox vaccines do, both because of their simplicity and from more than two centuries of experience. The far more complex and intrusive process of genome editing can do myriad things we cannot anticipate, including creating new population-level vulnerabilities to infrequent viral or bacterial infections. Much more experimentation and caution would therefore be necessary before moving forward even with the most basic interventions.
Second and in my mind more fundamentally, vaccines are a public health intervention, whereas genome editing, at least in the foreseeable future, will be something enjoyed by the privileged few create and propagate privilege in ways that we have not even conceived.
These two principles together create a clear set of guidelines for how we may want to approach germline editing. First, make sure, extra sure and then double extra sure that unforeseen consequences are limited both in number and scope. This requires not just research by individual scientists and labs, but a public infrastructure to do an even more rigorous testing and permission process than the Food and Drug Administration (FDA) is currently implementing for drugs and vaccines. Second, legislate and enforce the norms within the scientific and medical community that germline editing should be seen as only and only as a public health measure. No germline editing services should be allowed to be purchased in the private market, and any well-tested and understood beneficial genome-engineering intervention should be made available to all (and associated with an accurate and widely available information campaign, in the way that vaccines were initially supported).
Implementing these guidelines isn’t pie-in-the-sky. We already have institutions that house relevant expertise and are well respected and norms within the scientific community are aligned with these bodies (which doesn’t of course mean that some irresponsible, risk-taking individual scientists wouldn’t try to break the laws and regulations).
These bodies include the US National Academies of Sciences, Engineering, and Medicine and the FDA, both of which have published highly visible reports and guidelines for research and practice in this area. The International Summit on Human Gene Editing, held in Washington in December 2015 and convened by the US, UK, and Chinese academies, adopted a hard line against germline engineering, especially the alteration of gametes and embryos that would generate heritable advantages for the privileged few. Subsequent summits in Hong Kong (2018), where the He Jiankui case broke, and London (2023) have reaffirmed and refined that stance.
The reason why I find the challenge in the area of designer babies a little more manageable than the ongoing changes in artificial intelligence is precisely that such bodies exist, have been proactive and are respected and listened to by the majority of scientists in the area. The tragedy in AI is that we are at the cusp of similarly transformative changes, with equally far-ranging implications, but there are no equivalent bodies with authority (AI safety institutes and EU-convened bodies lack the authority to influence the industry meaningfully) and individual scientists and labs appear to be oblivious to the societal effects that they may unleash.
We need the same urgency when it comes to taking the systemic, ethically-clear stance against AI risks. Such a stance could also facilitate dealing with the various symbiotic challenges of genetic engineering.